Harrow’s (HROW) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Harrow (NASDAQ:HROW) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $64.00 target price on the stock.

Other research analysts also recently issued research reports about the company. B. Riley increased their price target on Harrow from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. Cantor Fitzgerald assumed coverage on Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price target for the company. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 12th. Craig Hallum increased their price target on Harrow from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. Finally, BTIG Research reiterated a “buy” rating and set a $63.00 price target on shares of Harrow in a research note on Wednesday, September 24th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $68.50.

Harrow Stock Up 0.4%

HROW stock opened at $48.37 on Monday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -193.48 and a beta of 0.27. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The stock has a fifty day moving average of $39.17 and a 200-day moving average of $31.91.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.23. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Harrow will post -0.53 earnings per share for the current year.

Institutional Trading of Harrow

A number of institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its holdings in Harrow by 10.3% during the 2nd quarter. Osaic Holdings Inc. now owns 24,031 shares of the company’s stock worth $734,000 after purchasing an additional 2,249 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after acquiring an additional 2,615 shares in the last quarter. Engineers Gate Manager LP raised its holdings in shares of Harrow by 194.7% in the 2nd quarter. Engineers Gate Manager LP now owns 35,565 shares of the company’s stock valued at $1,086,000 after acquiring an additional 23,495 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Harrow by 266.8% in the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock valued at $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Harrow in the 2nd quarter valued at about $48,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.